Surveillance and management of de novo malignancy after liver transplantation

Liver transplantation (LT) has significantly improved long-term survival rates, but recipients face increased risks of de novo malignancy (DNM) due to immunosuppression.DNM patterns differ worldwide, with post-transplant lymphoproliferative disorder common in Western countries, while South Korea sees more gastric and colorectal cancers.Risk factors include immunosuppressive drugs, underlying conditions, and lifestyle factors.Screening strategies should be tailored to regional DNM patterns, with regular surveillance crucial for early detection and management.Minimizing immunosuppressant usage and prompt local treatment upon DNM detection offer favorable outcomes for LT recipients.